Research programme: oxazolidinone antibacterials - Johnson & Johnson
Alternative Names: JNJ 10283104; JNJ 10391849; RWJ-416457Latest Information Update: 16 Jul 2016
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Oxazolidinones
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 28 Oct 2008 Antimicrobial data from a preclinical trial presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
- 23 Apr 2007 Preclinical data added to the Bacterial Infections antimicrobial activity section